Sign Up to like & get recommendations! 1
Published in 2022 at "ChemBioChem"
DOI: 10.1002/cbic.202200092
Abstract: Antibodies are a significant and growing sector within the global pharmaceutical industry. The popularity of antibodies as therapeutics derives from – at least in part – evolvable affinity for virtually any disease‐relevant cell surface receptor,… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "Engineering in Life Sciences"
DOI: 10.1002/elsc.201600255
Abstract: To engineer a host cell line that produces defucosylated mAbs with superior antibody‐dependent cellular cytotoxicity, we disrupted α‐1, 6 fucosyltransferase (FUT8) gene in CHO‐S (CHO is Chinese hamster ovary) cells by clustered regularly interspaced short… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "Methods in molecular biology"
DOI: 10.1007/978-1-4939-6881-7_30
Abstract: Mast cells are key effector cells in inflammation that can be activated by specific antigens via IgE or IgG binding on their FcR. Aggregation of mast cell Fc receptors by cell-bound antigens induces mast cell… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Methods in molecular biology"
DOI: 10.1007/978-1-4939-8979-9_12
Abstract: Antibody-dependent cell-mediated cytotoxicity (ADCC) is a mechanism in which immune cell activation is induced by the cross-linking of CD16 with the Fc region of antibodies that at the same time bind specifically to cell surface… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Methods in molecular biology"
DOI: 10.1007/978-1-4939-8979-9_13
Abstract: Antibody-dependent cell-mediated cytotoxicity (ADCC) is a mechanism in which immune cell activation is induced by the cross-linking of CD16 with the Fc region of antibodies that at the same time bind specifically to cell surface… read more here.
Sign Up to like & get recommendations! 0
Published in 2022 at "Molecular biology reports"
DOI: 10.1007/s11033-022-07280-w
Abstract: BACKGROUND Obinutuzumab, a Type II anti-CD20 antibody, is used to treat follicular lymphoma. A major mode of action of obinutuzumab is antibody-dependent cellular cytotoxicity (ADCC). Knowledge of the mechanisms of resistance to obinutuzumab is important… read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "Cell reports"
DOI: 10.1016/j.celrep.2018.07.035
Abstract: Some monoclonal antibodies (mAbs) recovered from survivors of filovirus infections can protect against infection. It is currently unknown whether natural infection also induces some antibodies with the capacity for antibody-dependent enhancement (ADE). A panel of… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Current opinion in virology"
DOI: 10.1016/j.coviro.2019.02.002
Abstract: Dengue virus (DENV) consists of four serotypes. Sequential serotype infections can cause increased disease severity, likely due to antibody-dependent enhancement (ADE) of infection. Here, we review two recent papers showing major advancements in the understanding… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "EBioMedicine"
DOI: 10.1016/j.ebiom.2019.08.072
Abstract: Background Antibody-dependent cellular cytotoxicity (ADCC) has been associated with improved infant outcome in mother-to-child transmission (MTCT) of HIV-1. Epitopes of these ADCC-mediating antibodies remain unidentified. CD4-inducible (CD4i) epitopes on gp120 are common ADCC targets in… read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "International Journal of Infectious Diseases"
DOI: 10.1016/j.ijid.2020.09.015
Abstract: Antibody-dependent enhancement (ADE) exists in several kinds of virus. It has a negative influence on antibody therapy for viral infection. This effect was first identified in dengue virus and then was also described for coronavirus.… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "International immunopharmacology"
DOI: 10.1016/j.intimp.2021.108112
Abstract: More than 100 monoclonal antibodies (mAbs) have been approved by FDA. The mechanism of action (MoA) involves in neutralization of a specific target via the Fab region and Fc effector functions through Fc region, while… read more here.